AURA Aura Biosciences, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1501796 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-28.6%
TTM EPS YoY16.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-61.7%
ROA-53.5%
ROIC (approx.)-64.7%
Asset turnover—
Leverage & solvency
Liabilities / assets10.6%
Debt / equity0.00x
Current ratio14.21x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.80x
Accruals ratio-10.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $90.30M | $73.30M |
| SG&A expense | $22.49M | $22.81M |
| Operating income | -$112.79M | -$96.12M |
| Pretax income | -$106.08M | -$86.81M |
| Income tax | $108,000 | $112,000 |
| Net income | -$106.19M | -$86.92M |
| EBITDA | -$111.66M | -$94.89M |
| EPS (basic) | -1.76 | -1.75 |
| EPS (diluted) | -1.76 | -1.75 |
| Weighted avg. shares (diluted) | 60.34M | 49.65M |
| Balance sheet | ||
| Cash & equivalents | $59.52M | $31.69M |
| Current assets | $149.74M | $160.62M |
| PP&E, net | $2.62M | $3.21M |
| Total assets | $169.43M | $182.50M |
| Current liabilities | $18.38M | $14.91M |
| Total liabilities | $32.52M | $30.53M |
| Shareholders' equity | $136.91M | $151.97M |
| Shares outstanding | 63.59M | 50.00M |
| Cash flow statement | ||
| Operating cash flow | -$84.74M | -$79.81M |
| Capital expenditure | $447,000 | $1.25M |
| Free cash flow | -$85.19M | -$81.06M |
| Investing cash flow | $35.59M | $68.82M |
| Financing cash flow | $77.16M | $1.59M |
| Depreciation & amortization | $1.13M | $1.22M |
| Stock-based compensation | $14.32M | $11.72M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.